Therapeutic dose of omalizumab = 20 x [IgE]: Is the equation correct or is enough too little?;Therapeutische dosis von omalizumab = 20 x [IgE]: Stimmt die Gleichung oder ist genug zu wenig?

Pneumologie

Volumn 58, Issue 8, 2004, Pages 543-545

  Kroegel, C ^a   Reissig A ^a   Henzgen, M ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

DRUG DOSE REGIMEN; EDITORIAL; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RHINITIS, ALLERGIC, SEASONAL;

EID: 4344588236     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818481     Document Type: Editorial

References (22)

1. Kroegel C. Asthma bronchiale. Pathogenetische Grundlagen, Diagnostik und Therapie, 2. überarbeitete und erweiterte Auflage. Stuttgart, New York: Thieme, 2002
2. Kroegel C, Foerster M, Workalemahu G et al. Grundlagen der asthmatischen Entzündung. Z ärztl Fortbild Qualitätssich 2001; 95: 677-683
3. Presta L, Lahr S, Shields R et al. Humanization of an antibody directed against Immunoglobulin E. J Immunol 1993; 151: 2623-2632
4. Banyash M, Kerhy M, Eshar Z. Anti-IgE monoclonal antibodies directed at the Fcε-receptor binding site. Mol Immunol 1988; 25: 705-711
5. Coyle AJ, Wagner K, Bertrand C et al. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and Th2 cell cytikine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996; 183: 1303-1310
6. Fox JA, Hotaling TE, Struble C et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279: 1000-1008
7. MacGlashan Jr DW, Bochner B, Adelman D et al. Down-regulation of FcεRI expression on human basophils during anti-IgE antibody therapy. J Immunol 1997; 158: 1438-1445
8. Corne J, Djukanovic R, Thomas L et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99: 879-887
9. Hochhaus G, Brookman L, Fox H et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003; 19: 491-498
10. Beeh KM, Beier J, Buhl R. Saisonale Schwankungen des Serum-IgE-Spiegels und deren mögliche Bedeutung für die Berechnung der therapeutischen Dosis von Omalizumab (rhuMab-E25, anti-IgE). Pneumologie 2004; 58: 546-551
11. Hayashi M, Ohashi Y, Tanaka A et al. Suppression of seasonal increase in serum interleukin-5 is linked to the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Acta Otolaryngol Suppl 1998; 538: 133-142
12. Masamoto T, Ohashi Y, Nakai Y. Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1 in sera in patients with seasonal allergic rhinitis. Ann Otol Rhinol Laryngol 1999; 108: 169-176
13. Ohashi Y, Tanaka A, Kakinoki Y et al. Serum level of soluble interleukin-2 receptor in patients with seasonal allergic rhinitis. Scand J Immunol 1997; 45: 315-321
14. Deuschl H. Immunoglobulins in nasal secretion with special reference to IgE. II. Seasonal studies of Timothy-specific IgE-antibody in patients with allergic rhinitis. Int Arch Allergy Appl Immunol 1976; 52: 376-383
15. Marcucci F, Sensi LG, Migali E et al. Eosinophil cationic protein and specific IgE in serum and nasal mucosa of patients with grass-pollen-allergic rhinitis and asthma. Allergy 2001; 56: 231-236
16. Lin H, Boesel KM, Griffith DT et al. Omalizumab rapidly decreases nasal allergic response and FceRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302
17. Wenzel S, Bousquet J, Freeman P et al. Factors predictive of response to omalizumab therapy in patients with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2002; 109: A458
18. Casale TB, Bernstein IL, Busse WW et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110-121
19. Prussin C, Griffith DT, Boesel KM et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 1147-1154
20. Kroegel C, Mock B, Reißig A et al. Antikörper bei allergischen Erkrankungen. Selektive Hemmung IgE-vermittelter Reaktionen durch humanisierte Anti-IgE-Antikörper. Arzneimittelth 2002; 20: 226-237
21. Lodrup-Carlsen KC, Halvorsen R, Ahlstedt S et al. Eosinophil cationic protein and tidal flow volume loops in children 0-2 years of age. Eur Respir J 1995; 8: 1148-1154
22. Walker S, Monteil M, Phelan K et al. Anti-IgE for chronic asthma. Cochrane Database Syst Rev 2003; (3): CD003559